Long-term follow-up of gastric MALT lymphoma after H. pylori eradication
For almost 10 years, we have been familiar with the concept of mucosa-associated lymphoid tissue (MALT)-type lymphoma of the stomach caused by chronic Helicobacter pylori infection. Many epidemiologic, biologic, and molecular genetic studies have implicated H. pylori for its role in lymphoma genesis...
Gespeichert in:
| Veröffentlicht in: | Current gastroenterology reports 2001-12, Vol.3 (6), p.516-522 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 522 |
|---|---|
| container_issue | 6 |
| container_start_page | 516 |
| container_title | Current gastroenterology reports |
| container_volume | 3 |
| creator | Morgner, A Thiede, C Bayerdörffer, E Alpen, B Wündisch, T Neubauer, A Stolte, M |
| description | For almost 10 years, we have been familiar with the concept of mucosa-associated lymphoid tissue (MALT)-type lymphoma of the stomach caused by chronic Helicobacter pylori infection. Many epidemiologic, biologic, and molecular genetic studies have implicated H. pylori for its role in lymphoma genesis. Since the first reports on complete remission of gastric MALT lymphomas after cure of bacterial infection, many clinical studies have investigated the effect of eradicating H. pylori on the course of MALT lymphoma, and indeed were able to confirm remission of the lymphoma. To date, more than 650 patients worldwide have been treated for gastric MALT lymphoma with antibiotics, and we have gained many new insights concerning the biologic behavior of this disease, especially from the deepened knowledge of cytogenetics. Furthermore, factors relevant for the prediction of treatment outcome have been identified, which has helped to stratify patients into risk groups. |
| doi_str_mv | 10.1007/s11894-001-0073-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72256535</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72256535</sourcerecordid><originalsourceid>FETCH-LOGICAL-c240t-9fc57d76e98265b27aa4e86d2cb3c394dca8015e9c322303bab060fd70c4e5803</originalsourceid><addsrcrecordid>eNpdkM9LwzAUx4Mobk7_AC8SELxl5kfTNMcx1AkVLxO8hTRNZ0fb1KRF9t-bsoHg4fHe4fN9vPcB4JbgJcFYPAZCMpkgjEkswZA8A3PCWYIYoZ_n00wpyjATM3AVwh5jGrH0EswISWVKJZ6DTe66HRqsb2Hlmsb9oLGHroI7HQZfG_i2yrewObT9l2s11FUk4WYJ-0PjfA2t12Vt9FC77hpcVLoJ9ubUF-Dj-Wm73qD8_eV1vcqRoQkekKwMF6VIrcxoygsqtE5slpbUFMwwmZRGZ5hwKw2jlGFW6AKnuCoFNonl8ZcFeDju7b37Hm0YVFsHY5tGd9aNQQlKecoZj-D9P3DvRt_F2xSVJBNcSiIjRY6U8S4EbyvV-7rV_qAIVpNkdZSsomQ1SVZT5u60eSxaW_4lTlbZL3YSdcw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2918759919</pqid></control><display><type>article</type><title>Long-term follow-up of gastric MALT lymphoma after H. pylori eradication</title><source>MEDLINE</source><source>ProQuest Central (Alumni)</source><source>ProQuest Central UK/Ireland</source><source>SpringerLink Journals - AutoHoldings</source><source>ProQuest Central</source><creator>Morgner, A ; Thiede, C ; Bayerdörffer, E ; Alpen, B ; Wündisch, T ; Neubauer, A ; Stolte, M</creator><creatorcontrib>Morgner, A ; Thiede, C ; Bayerdörffer, E ; Alpen, B ; Wündisch, T ; Neubauer, A ; Stolte, M</creatorcontrib><description>For almost 10 years, we have been familiar with the concept of mucosa-associated lymphoid tissue (MALT)-type lymphoma of the stomach caused by chronic Helicobacter pylori infection. Many epidemiologic, biologic, and molecular genetic studies have implicated H. pylori for its role in lymphoma genesis. Since the first reports on complete remission of gastric MALT lymphomas after cure of bacterial infection, many clinical studies have investigated the effect of eradicating H. pylori on the course of MALT lymphoma, and indeed were able to confirm remission of the lymphoma. To date, more than 650 patients worldwide have been treated for gastric MALT lymphoma with antibiotics, and we have gained many new insights concerning the biologic behavior of this disease, especially from the deepened knowledge of cytogenetics. Furthermore, factors relevant for the prediction of treatment outcome have been identified, which has helped to stratify patients into risk groups.</description><identifier>ISSN: 1522-8037</identifier><identifier>EISSN: 1534-312X</identifier><identifier>DOI: 10.1007/s11894-001-0073-9</identifier><identifier>PMID: 11696290</identifier><language>eng</language><publisher>United States: Springer Nature B.V</publisher><subject>Follow-Up Studies ; Helicobacter Infections - complications ; Helicobacter Infections - drug therapy ; Helicobacter pylori ; Humans ; Lymphoma, B-Cell, Marginal Zone - drug therapy ; Lymphoma, B-Cell, Marginal Zone - etiology ; Stomach Neoplasms - drug therapy ; Stomach Neoplasms - etiology</subject><ispartof>Current gastroenterology reports, 2001-12, Vol.3 (6), p.516-522</ispartof><rights>Current Science Inc 2001.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c240t-9fc57d76e98265b27aa4e86d2cb3c394dca8015e9c322303bab060fd70c4e5803</citedby><cites>FETCH-LOGICAL-c240t-9fc57d76e98265b27aa4e86d2cb3c394dca8015e9c322303bab060fd70c4e5803</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2918759919?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,21388,21389,27924,27925,33530,33531,33744,33745,43659,43805,64385,64387,64389,72341</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11696290$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Morgner, A</creatorcontrib><creatorcontrib>Thiede, C</creatorcontrib><creatorcontrib>Bayerdörffer, E</creatorcontrib><creatorcontrib>Alpen, B</creatorcontrib><creatorcontrib>Wündisch, T</creatorcontrib><creatorcontrib>Neubauer, A</creatorcontrib><creatorcontrib>Stolte, M</creatorcontrib><title>Long-term follow-up of gastric MALT lymphoma after H. pylori eradication</title><title>Current gastroenterology reports</title><addtitle>Curr Gastroenterol Rep</addtitle><description>For almost 10 years, we have been familiar with the concept of mucosa-associated lymphoid tissue (MALT)-type lymphoma of the stomach caused by chronic Helicobacter pylori infection. Many epidemiologic, biologic, and molecular genetic studies have implicated H. pylori for its role in lymphoma genesis. Since the first reports on complete remission of gastric MALT lymphomas after cure of bacterial infection, many clinical studies have investigated the effect of eradicating H. pylori on the course of MALT lymphoma, and indeed were able to confirm remission of the lymphoma. To date, more than 650 patients worldwide have been treated for gastric MALT lymphoma with antibiotics, and we have gained many new insights concerning the biologic behavior of this disease, especially from the deepened knowledge of cytogenetics. Furthermore, factors relevant for the prediction of treatment outcome have been identified, which has helped to stratify patients into risk groups.</description><subject>Follow-Up Studies</subject><subject>Helicobacter Infections - complications</subject><subject>Helicobacter Infections - drug therapy</subject><subject>Helicobacter pylori</subject><subject>Humans</subject><subject>Lymphoma, B-Cell, Marginal Zone - drug therapy</subject><subject>Lymphoma, B-Cell, Marginal Zone - etiology</subject><subject>Stomach Neoplasms - drug therapy</subject><subject>Stomach Neoplasms - etiology</subject><issn>1522-8037</issn><issn>1534-312X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkM9LwzAUx4Mobk7_AC8SELxl5kfTNMcx1AkVLxO8hTRNZ0fb1KRF9t-bsoHg4fHe4fN9vPcB4JbgJcFYPAZCMpkgjEkswZA8A3PCWYIYoZ_n00wpyjATM3AVwh5jGrH0EswISWVKJZ6DTe66HRqsb2Hlmsb9oLGHroI7HQZfG_i2yrewObT9l2s11FUk4WYJ-0PjfA2t12Vt9FC77hpcVLoJ9ubUF-Dj-Wm73qD8_eV1vcqRoQkekKwMF6VIrcxoygsqtE5slpbUFMwwmZRGZ5hwKw2jlGFW6AKnuCoFNonl8ZcFeDju7b37Hm0YVFsHY5tGd9aNQQlKecoZj-D9P3DvRt_F2xSVJBNcSiIjRY6U8S4EbyvV-7rV_qAIVpNkdZSsomQ1SVZT5u60eSxaW_4lTlbZL3YSdcw</recordid><startdate>200112</startdate><enddate>200112</enddate><creator>Morgner, A</creator><creator>Thiede, C</creator><creator>Bayerdörffer, E</creator><creator>Alpen, B</creator><creator>Wündisch, T</creator><creator>Neubauer, A</creator><creator>Stolte, M</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>200112</creationdate><title>Long-term follow-up of gastric MALT lymphoma after H. pylori eradication</title><author>Morgner, A ; Thiede, C ; Bayerdörffer, E ; Alpen, B ; Wündisch, T ; Neubauer, A ; Stolte, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c240t-9fc57d76e98265b27aa4e86d2cb3c394dca8015e9c322303bab060fd70c4e5803</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Follow-Up Studies</topic><topic>Helicobacter Infections - complications</topic><topic>Helicobacter Infections - drug therapy</topic><topic>Helicobacter pylori</topic><topic>Humans</topic><topic>Lymphoma, B-Cell, Marginal Zone - drug therapy</topic><topic>Lymphoma, B-Cell, Marginal Zone - etiology</topic><topic>Stomach Neoplasms - drug therapy</topic><topic>Stomach Neoplasms - etiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Morgner, A</creatorcontrib><creatorcontrib>Thiede, C</creatorcontrib><creatorcontrib>Bayerdörffer, E</creatorcontrib><creatorcontrib>Alpen, B</creatorcontrib><creatorcontrib>Wündisch, T</creatorcontrib><creatorcontrib>Neubauer, A</creatorcontrib><creatorcontrib>Stolte, M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medicine (ProQuest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Current gastroenterology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Morgner, A</au><au>Thiede, C</au><au>Bayerdörffer, E</au><au>Alpen, B</au><au>Wündisch, T</au><au>Neubauer, A</au><au>Stolte, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term follow-up of gastric MALT lymphoma after H. pylori eradication</atitle><jtitle>Current gastroenterology reports</jtitle><addtitle>Curr Gastroenterol Rep</addtitle><date>2001-12</date><risdate>2001</risdate><volume>3</volume><issue>6</issue><spage>516</spage><epage>522</epage><pages>516-522</pages><issn>1522-8037</issn><eissn>1534-312X</eissn><abstract>For almost 10 years, we have been familiar with the concept of mucosa-associated lymphoid tissue (MALT)-type lymphoma of the stomach caused by chronic Helicobacter pylori infection. Many epidemiologic, biologic, and molecular genetic studies have implicated H. pylori for its role in lymphoma genesis. Since the first reports on complete remission of gastric MALT lymphomas after cure of bacterial infection, many clinical studies have investigated the effect of eradicating H. pylori on the course of MALT lymphoma, and indeed were able to confirm remission of the lymphoma. To date, more than 650 patients worldwide have been treated for gastric MALT lymphoma with antibiotics, and we have gained many new insights concerning the biologic behavior of this disease, especially from the deepened knowledge of cytogenetics. Furthermore, factors relevant for the prediction of treatment outcome have been identified, which has helped to stratify patients into risk groups.</abstract><cop>United States</cop><pub>Springer Nature B.V</pub><pmid>11696290</pmid><doi>10.1007/s11894-001-0073-9</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1522-8037 |
| ispartof | Current gastroenterology reports, 2001-12, Vol.3 (6), p.516-522 |
| issn | 1522-8037 1534-312X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72256535 |
| source | MEDLINE; ProQuest Central (Alumni); ProQuest Central UK/Ireland; SpringerLink Journals - AutoHoldings; ProQuest Central |
| subjects | Follow-Up Studies Helicobacter Infections - complications Helicobacter Infections - drug therapy Helicobacter pylori Humans Lymphoma, B-Cell, Marginal Zone - drug therapy Lymphoma, B-Cell, Marginal Zone - etiology Stomach Neoplasms - drug therapy Stomach Neoplasms - etiology |
| title | Long-term follow-up of gastric MALT lymphoma after H. pylori eradication |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T18%3A30%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20follow-up%20of%20gastric%20MALT%20lymphoma%20after%20H.%20pylori%20eradication&rft.jtitle=Current%20gastroenterology%20reports&rft.au=Morgner,%20A&rft.date=2001-12&rft.volume=3&rft.issue=6&rft.spage=516&rft.epage=522&rft.pages=516-522&rft.issn=1522-8037&rft.eissn=1534-312X&rft_id=info:doi/10.1007/s11894-001-0073-9&rft_dat=%3Cproquest_cross%3E72256535%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2918759919&rft_id=info:pmid/11696290&rfr_iscdi=true |